BVS RSI Chart
Last 7 days
17.8%
Last 30 days
35.3%
Last 90 days
40.4%
Trailing 12 Months
335.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 522.7M | 0 | 0 | 0 |
2023 | 513.9M | 510.6M | 502.8M | 512.3M |
2022 | 466.4M | 496.9M | 516.7M | 512.1M |
2021 | 324.3M | 376.1M | 399.1M | 430.9M |
2020 | 335.4M | 330.7M | 325.9M | 321.2M |
2019 | 0 | 0 | 0 | 340.1M |
2018 | 0 | 0 | 0 | 319.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 11, 2024 | singleton mark leonard | sold | -19,000 | 4.75 | -4,000 | svp & cfo |
Apr 11, 2024 | d'adamio anthony | sold | -14,506 | 4.75 | -3,054 | svp & general counsel |
Apr 11, 2024 | church katrina j | sold | -6,293 | 4.75 | -1,325 | svp & chief compliance officer |
Apr 10, 2024 | church katrina j | acquired | - | - | 4,300 | svp & chief compliance officer |
Apr 10, 2024 | singleton mark leonard | acquired | - | - | 13,000 | svp & cfo |
Apr 10, 2024 | d'adamio anthony | acquired | - | - | 9,925 | svp & general counsel |
Mar 22, 2024 | singleton mark leonard | sold | -29,852 | 5.3876 | -5,541 | svp & cfo |
Mar 21, 2024 | singleton mark leonard | acquired | - | - | 18,625 | svp & cfo |
Mar 15, 2024 | church katrina j | sold | -6,644 | 5.46 | -1,217 | svp & chief compliance officer |
Mar 15, 2024 | d'adamio anthony | sold | -17,062 | 5.46 | -3,125 | svp & general counsel |
Which funds bought or sold BVS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | unchanged | - | -6,160 | 457,600 | -% |
May 16, 2024 | Arete Wealth Advisors, LLC | sold off | -100 | -69,037 | - | -% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 147 | 1,181,070 | 2,001,350 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 39.8 | 7,225 | 26,265 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | added | 24.39 | 101,807 | 549,536 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 133 | 1,616,050 | 2,857,050 | -% |
May 15, 2024 | Point72 Asia (Singapore) Pte. Ltd. | added | 4,691 | 254,638 | 260,140 | 0.07% |
May 15, 2024 | Laurion Capital Management LP | unchanged | - | -8,281 | 615,113 | -% |
May 15, 2024 | MARSHALL WACE, LLP | added | 26.13 | 245,683 | 1,250,330 | -% |
May 15, 2024 | 683 Capital Management, LLC | sold off | -100 | -297,170 | - | -% |
Unveiling Bioventus Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bioventus Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.0M | 3.7M | -0.09 | 0.28 |
Bioventus Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Revenue | -4.4% | 129,457 | 135,423 | 120,794 | 137,069 | 119,059 | 125,834 | 128,662 | 140,331 | 117,290 | 130,414 | 108,890 | 109,816 | 81,778 | 98,591 | 85,908 | 58,017 | 78,645 | - | - |
Gross Profit | 2.4% | 88,380 | 86,301 | 78,850 | 89,123 | 73,919 | 74,189 | 84,535 | 96,654 | 75,702 | 87,768 | 79,069 | 76,313 | 59,556 | 73,470 | 62,464 | 40,349 | 57,236 | - | - |
S&GA Expenses | 0.1% | 78,406 | 78,357 | 69,820 | 74,844 | 80,858 | 77,435 | 78,955 | 89,620 | 86,124 | 80,881 | 69,636 | 69,050 | 34,686 | 61,974 | 50,295 | 40,533 | 40,276 | - | - |
R&D Expenses | -20.4% | 2,597 | 3,262 | 3,015 | 3,398 | 3,771 | 5,946 | 4,614 | 6,366 | 6,928 | 7,103 | 6,153 | 4,836 | 947 | 2,891 | 3,569 | 2,596 | 2,146 | - | - |
EBITDA Margin | 84.7% | -0.03* | -0.22* | -0.27* | -0.51* | -0.51* | -0.35* | -0.29* | -0.04* | -0.05* | 0.04* | 0.06* | 0.09* | 0.12* | 0.07* | 0.05* | 0.05* | 0.05* | 0.05* | 0.05* |
Income Taxes | 220.9% | 907 | -750 | 600 | 381 | -146 | -10,963 | -29,523 | 1,244 | -5,132 | -2,725 | -882 | 1,714 | -73.00 | 890 | 373 | -110 | 39.00 | - | - |
Earnings Before Taxes | 39.6% | -5,075 | -8,406 | -8,191 | -4,350 | -100,164 | -32,440 | -130,558 | -6,490 | -19,537 | -2,750 | -3,151 | -9,066 | 24,455 | 3,141 | 8,338 | -6,090 | 10,525 | - | - |
EBT Margin | 78.9% | -0.05* | -0.24* | -0.29* | -0.52* | -0.52* | -0.37* | -0.31* | -0.06* | -0.07* | 0.02* | 0.04* | 0.07* | 0.09* | 0.05* | 0.03* | 0.03* | 0.03* | 0.03* | 0.02* |
Net Income | 1.9% | -5,982 | -6,096 | -7,303 | -3,681 | -139,150 | -31,930 | -108,245 | -7,252 | -11,277 | -364 | -1,071 | -4,126 | -1,041 | 2,776 | 8,457 | -5,766 | 10,944 | - | - |
Net Income Margin | 85.5% | -0.04* | -0.30* | -0.36* | -0.55* | -0.56* | -0.31* | -0.25* | -0.04* | -0.04* | -0.02* | 0.04* | 0.04* | 0.05* | 0.05* | 0.02* | 0.02* | 0.02* | 0.02* | -0.04* |
Free Cashflow | -162.9% | -6,296 | 10,005 | -10,351 | 9,398 | -1,070 | 1,841 | -2,350 | 909 | -23,979 | 4,165 | 8,661 | 16,057 | -19,412 | 11,199 | 19,560 | 7,069 | 17,392 | - | - |
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | -2.1% | 794 | 811 | 811 | 837 | 887 | 1,373 | 1,398 | 1,209 | 1,197 | 1,226 | 655 | 647 | 643 | 494 | 472 |
Current Assets | -0.8% | 266 | 268 | 249 | 261 | 309 | 273 | 271 | 277 | 245 | 263 | 246 | 290 | 271 | 212 | 183 |
Cash Equivalents | -31.9% | 25.00 | 37.00 | 27.00 | 29.00 | 47.00 | 30.00 | 34.00 | 41.00 | 83.00 | 99.00 | 131 | 138 | 129 | 87.00 | 65.00 |
Inventory | 6.2% | 97.00 | 91.00 | 98.00 | 96.00 | 88.00 | 85.00 | 77.00 | 69.00 | 65.00 | 62.00 | 37.00 | 34.00 | 40.00 | 29.00 | 27.00 |
Net PPE | - | - | - | - | - | - | - | - | - | 25.00 | 23.00 | 10.00 | 9.00 | 8.00 | 7.00 | 4.00 |
Goodwill | 0% | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 15.00 | 60.00 | 148 | 148 | 53.00 | 52.00 | 3.00 | 50.00 | 50.00 |
Liabilities | -2.2% | 577 | 590 | 585 | 604 | 647 | 960 | 1,019 | 689 | 675 | 618 | 424 | 427 | 423 | 350 | 327 |
Current Liabilities | -1.2% | 173 | 175 | 161 | 179 | 196 | 304 | 288 | 199 | 172 | 181 | 161 | 158 | 149 | 123 | 89.00 |
Long Term Debt | -3.2% | 355 | 367 | 375 | 375 | 404 | 385 | 393 | 351 | 348 | 340 | 162 | 166 | 170 | 173 | 188 |
LT Debt, Current | 28.6% | 36.00 | 28.00 | 20.00 | 11.00 | 41.00 | 33.00 | 31.00 | 23.00 | 20.00 | 18.00 | 15.00 | 15.00 | 15.00 | 15.00 | 10.00 |
LT Debt, Non Current | -100.0% | - | 367 | 375 | 375 | 404 | 385 | 393 | 351 | 348 | 340 | 162 | 166 | 170 | 173 | 188 |
Shareholder's Equity | 25.3% | 217 | 174 | 178 | 233 | 240 | 325 | 451 | 592 | 594 | 608 | 230 | 219 | 220 | 144 | 143 |
Retained Earnings | -1.4% | -326 | -321 | -315 | -308 | -304 | -165 | -133 | -25.13 | -17.88 | -6.60 | -6.24 | -5.17 | -1.04 | -144 | -141 |
Additional Paid-In Capital | 0.6% | 497 | 494 | 492 | 491 | 492 | 491 | 478 | 474 | 468 | 473 | 158 | 146 | 143 | - | - |
Shares Outstanding | 1.2% | 63.00 | 63.00 | 63.00 | 62.00 | 62.00 | 61.00 | 61.00 | 61.00 | 60.00 | 45.00 | 42.00 | 42.00 | 42.00 | - | - |
Minority Interest | -2.9% | 46.00 | 48.00 | 49.00 | 50.00 | 52.00 | 87.00 | 36.00 | 72.00 | 72.00 | 141 | 78.00 | 78.00 | 78.00 | 2.00 | 3.00 |
Float | - | - | - | - | 75.00 | - | - | - | 206 | - | - | - | 263 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Cashflow From Operations | -157.9% | -6,005 | 10,374 | -8,315 | 10,795 | 2,490 | 5,244 | -701 | 2,939 | -21,019 | 13,117 | 10,587 | 17,329 | -18,042 | 25,447 | 20,841 | 7,820 | 17,691 | - | - |
Share Based Compensation | 46.0% | 2,591 | 1,775 | 1,833 | -2,732 | 1,846 | 3,432 | 4,648 | 4,616 | 4,889 | 6,109 | 5,938 | 5,853 | 1,944 | - | - | - | - | - | - |
Cashflow From Investing | -69.2% | -1,000 | -591 | -2,036 | 33,500 | -15,066 | -3,403 | -56,334 | -52,025 | -4,674 | -221,278 | -13,186 | -2,648 | -46,648 | -1,711 | -17,759 | -579 | -451 | - | - |
Cashflow From Financing | -30200.0% | -4,242 | -14.00 | 8,229 | -62,248 | 27,380 | -5,438 | 50,654 | 7,655 | 9,205 | 176,308 | -4,346 | -6,117 | 107,526 | -9,878 | -57,116 | -11,357 | 48,782 | - | - |
Consolidated Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 30, 2024 | Apr. 01, 2023 | |
Income Statement [Abstract] | ||
Net sales | $ 129,457 | $ 119,059 |
Cost of sales (including depreciation and amortization of $10,025 and $14,339, respectively) | 41,077 | 45,140 |
Gross profit | 88,380 | 73,919 |
Selling, general and administrative expense | 78,406 | 80,858 |
Research and development expense | 2,597 | 3,771 |
Restructuring costs | 0 | 317 |
Change in fair value of contingent consideration | 295 | 287 |
Depreciation and amortization | 1,755 | 2,129 |
Impairments of assets | 0 | 78,615 |
Operating income (loss) | 5,327 | (92,058) |
Interest expense, net | 10,339 | 9,694 |
Other expense (income) | 63 | (1,588) |
Other expense | 10,402 | 8,106 |
Loss before income taxes | (5,075) | (100,164) |
Income tax expense (benefit), net | 907 | (146) |
Net loss from continuing operations | (5,982) | (100,018) |
Loss from discontinued operations, net of tax | 0 | (74,429) |
Net loss | (5,982) | (174,447) |
Loss attributable to noncontrolling interest - continuing operations | 1,412 | 20,360 |
Loss attributable to noncontrolling interest - discontinued operations | 0 | 14,937 |
Net loss attributable to Bioventus Inc. | (4,570) | (139,150) |
Change in foreign currency translation adjustments | (585) | 657 |
Comprehensive loss | (6,567) | (173,790) |
Comprehensive loss attributable to noncontrolling interest - continuing operations | 1,528 | 20,226 |
Comprehensive loss attributable to noncontrolling interest - discontinued operations | 0 | 14,937 |
Comprehensive loss attributable to Bioventus Inc. | $ (5,039) | $ (138,627) |
Loss per share of Class A common stock | ||
Loss per share of Class A common stock from continuing operations, basic (in dollars per share) | $ (0.07) | $ (1.28) |
Loss per share of Class A common stock from continuing operations, diluted (in dollars per share) | (0.07) | (1.28) |
Loss per share of Class A common stock from discontinuing operations, basic (in dollars per share) | 0 | (0.96) |
Loss per share of Class A common stock from discontinuing operations, diluted (in dollars per share) | 0 | (0.96) |
Loss per share of class A common stock, basic (in dollars per share) | (0.07) | (2.24) |
Loss per share of class A common stock, diluted (in dollars per share) | $ (0.07) | $ (2.24) |
Weighted-average shares of Class A common stock outstanding | ||
Basic (in shares) | 63,380,187 | 62,124,752 |
Diluted (in shares) | 63,380,187 | 62,124,752 |
Consolidated Condensed Balance Sheets - USD ($) $ in Thousands | Mar. 30, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 25,173 | $ 36,964 |
Accounts receivable, net | 125,541 | 122,789 |
Inventory | 97,005 | 91,333 |
Prepaid and other current assets | 18,184 | 16,913 |
Total current assets | 265,903 | 267,999 |
Property and equipment, net | 34,532 | 36,605 |
Goodwill | 7,462 | 7,462 |
Intangible assets, net | 470,668 | 482,350 |
Operating lease assets | 12,462 | 13,353 |
Investment and other assets | 3,211 | 3,141 |
Total assets | 794,238 | 810,910 |
Current liabilities: | ||
Accounts payable | 19,099 | 23,038 |
Accrued liabilities | 113,605 | 119,795 |
Current portion of long-term debt | 35,811 | 27,848 |
Other current liabilities | 4,806 | 4,816 |
Total current liabilities | 173,321 | 175,497 |
Long-term debt, less current portion | 355,430 | 366,998 |
Deferred income taxes | 1,294 | 1,213 |
Contingent consideration | 18,445 | 18,150 |
Other long-term liabilities | 28,316 | 27,934 |
Total liabilities | 576,806 | 589,792 |
Commitments and contingencies (Note 11) | ||
Stockholders’ Equity | ||
Additional paid-in capital | 496,977 | 494,254 |
Accumulated deficit | (326,106) | (321,536) |
Accumulated other comprehensive income | 325 | 794 |
Total stockholders’ equity attributable to Bioventus Inc. | 171,276 | 173,591 |
Noncontrolling interest | 46,156 | 47,527 |
Total stockholders’ equity | 217,432 | 221,118 |
Total liabilities and stockholders’ equity | 794,238 | 810,910 |
Common Class A | ||
Stockholders’ Equity | ||
Common stock, value | 64 | 63 |
Common Class B | ||
Stockholders’ Equity | ||
Common stock, value | $ 16 | $ 16 |